Soy and phytoestrogens: Possible side effects;Soja und Phytoöstrogene: Mögliche Nebenwirkungen

GMS German Medical Science

Volumn 12, Issue , 2014, Pages 1-5

  Jargin, Sergei V ^a  

^a PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

Menopause; Nutrition; Phytoestrogens; Soy

Indexed keywords

ANIMALIA;

EID: 84964314993     PISSN: None     EISSN: 16123174     Source Type: Journal    
DOI: 10.3205/000203     Document Type: Article

References (58)

1. Patisaul HB, Jefferson W. The pros and cons of phytoestrogens. Front Neuroendocrinol. 2010 Oct; 31(4): 400-19. DOI: 10. 1016/j. yfrne. 2010. 03. 003.
2. Barnes S. The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol. 2010 Mar; 8(1): 89-98. DOI: 10. 1089/lrb. 2009. 0030.
3. Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, West L. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999 Mar; 84(3): 895-8. DOI: 10. 1210/jcem. 84. 3. 5561.
4. Cederroth CR, Zimmermann C, Nef S. Soy, phytoestrogens and their impact on reproductive health. Mol Cell Endocrinol. 2012 May; 355(2): 192-200. DOI: 10. 1016/j. mce. 2011. 05. 049.
5. Baber R. Phytoestrogens and post reproductive health. Maturitas. 2010 Aug; 66(4): 344-9. DOI: 10. 1016/j. maturitas. 2010. 03. 023.
6. Gencel VB, Benjamin MM, Bahou SN, Khalil RA. Vascular effects of phytoestrogens and alternative menopausal hormone therapy in cardiovascular disease. Mini Rev Med Chem. 2012 Feb; 12(2): 149-74. DOI: 10. 2174/138955712798995020.
7. Taku K, Melby MK, Kronenberg F, Kurzer MS, Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and metaanalysis of randomized controlled trials. Menopause. 2012 Jul; 19(7): 776-90. DOI: 10. 1097/gme. 0b013e3182410159.
8. Gold EB, Leung K, Crawford SL, Huang MH, Waetjen LE, Greendale GA. Phytoestrogen and fiber intakes in relation to incident vasomotor symptoms: results from the Study of Women's Health Across the Nation. Menopause. 2013 Mar; 20(3): 305-14. DOI: 10. 1097/GME. 0b013e31826d2f43.
9. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev. 2013; 12: CD001395. DOI: 10. 1002/14651858. CD001395. pub4.
10. Krebs EE, Ensrud KE, MacDonald R, Wilt TJ. Phytoestrogens for treatment of menopausal symptoms: a systematic review. Obstet Gynecol. 2004 Oct; 104(4): 824-36. DOI: 10. 1097/01. AOG. 0000140688. 71638. d3.
11. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidencebased review. Arch Gynecol Obstet. 2007 Nov; 276(5): 463-9. DOI: 10. 1007/s00404-007-0390-9.
12. Al-Azzawi F, Wahab M. Effectiveness of phytoestrogens in climacteric medicine. Ann N Y Acad Sci. 2010 Sep; 1205: 262-7. DOI: 10. 1111/j. 1749-6632. 2010. 05678. x.
13. Villaseca P. Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice. Climacteric. 2012 Apr; 15(2): 115-24. DOI: 10. 3109/13697137. 2011. 624214.
14. Speroff L. Alternative therapies for postmenopausal women. Int J Fertil Womens Med. 2005 May-Jun; 50(3): 101-14.
15. Poluzzi E, Piccinni C, Raschi E, Rampa A, Recanatini M, De Ponti F. Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective. Curr Med Chem. 2014; 21(4): 417-36. DOI: 10. 2174/09298673113206660297.
16. Guidozzi F, Alperstein A, Bagratee JS, Dalmeyer P, Davey M, De Villiers TJ, Hirschowitz S, Kopenhager T, Moodley SP, Roos P, Shaw A, Shimange O, Smith T, Thomas C, Titus J, Van der Spuy Z, Van Waart J. South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014. S Afr Med J. 2014 Aug; 104(8): 537-43. DOI: 10. 7196/samj. 8423.
17. Sirtori CR, Arnoldi A, Johnson SK. Phytoestrogens: end of a tale? Ann Med. 2005; 37(6): 423-38. DOI: 10. 1080/07853890510044586.
18. Davis SR. Phytoestrogen therapy for menopausal symptoms? BMJ. 2001 Aug; 323(7309): 354-5. DOI: 10. 1136/bmj. 323. 7309. 354.
19. Coxam V. Phyto-oestrogens and bone health. Proc Nutr Soc. 2008 May; 67(2): 184-95. DOI: 10. 1017/S0029665108007027.
20. Lagari VS, Levis S. Phytoestrogens in the prevention of postmenopausal bone loss. J Clin Densitom. 2013 Oct-Dec; 16(4): 445-9. DOI: 10. 1016/j. jocd. 2013. 08. 011.
21. Castelo-Branco C, Soveral I. Phytoestrogens and bone health at different reproductive stages. Gynecol Endocrinol. 2013 Aug; 29(8): 735-43. DOI: 10. 3109/09513590. 2013. 801441.
22. Song KB, Atkinson C, Frankenfeld CL, Jokela T, Wähälä K, Thomas WK, Lampe JW. Prevalence of daidzein-metabolizing phenotypes differs between Caucasian and Korean American women and girls. J Nutr. 2006 May; 136(5): 1347-51.
23. This P, de Cremoux P, Leclercq G, Jacquot Y. A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk. Maturitas. 2011 Nov; 70(3): 222-6. DOI: 10. 1016/j. maturitas. 2011. 07. 001.
24. Haimov-Kochman R, Brzezinski A, Hochner-Celnikier D. Herbal remedies for menopausal symptoms: are we cautious enough? Eur J Contracept Reprod Health Care. 2008 Jun; 13(2): 133-7. DOI: 10. 1080/13625180801920131.
25. Wilson S, Blaschek K, de Mejia E. Allergenic proteins in soybean: processing and reduction of P34 allergenicity. Nutr Rev. 2005 Feb; 63(2): 47-58. DOI: 10. 1111/j. 1753-4887. 2005. tb00121. x.
26. Saayman BD. The use of alternative lipid emulsions in paediatric and neonatal parenteral nutrition. S Afr J Clin Nutr. 2011; 24(3): S32-4.
27. Leclercq G, de Cremoux P, This P, Jacquot Y. Lack of sufficient information on the specificity and selectivity of commercial phytoestrogens preparations for therapeutic purposes. Maturitas. 2011 Jan; 68(1): 56-64. DOI: 10. 1016/j. maturitas. 2010. 10. 003.
28. Frigo P. News-Screen Menopause. Phytotherapie bei klimakterischen Beschwerden. J Gynakol Endokrinol. 2014; 8(3): 28-9.
29. Fusch C, Bauer K, Böhles HJ, Jochum F, Koletzko B, Krawinkel M, Krohn K, Mühlebach S; Working group for developing the guidelines for parenteral nutrition of The German Society for Nutritional Medicine. Neonatology/Paediatrics-Guidelines on Parenteral Nutrition, Chapter 13. GMS Ger Med Sci. 2009; 7: Doc15. DOI: 10. 3205/000074.
30. Usui T. Pharmaceutical prospects of phytoestrogens. Endocr J. 2006 Feb; 53(1): 7-20. DOI: 10. 1507/endocrj. 53. 7.
31. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr. 2010 Jul; 140(7): 1355S-62S. DOI: 10. 3945/jn. 109. 119776.
32. Adgent MA, Daniels JL, Edwards LJ, Siega-Riz AM, Rogan WJ. Early-life soy exposure and gender-role play behavior in children. Environ Health Perspect. 2011 Dec; 119(12): 1811-6. DOI: 10. 1289/ehp. 1103579.
33. Martinez J, Lewi JE. An unusual case of gynecomastia associated with soy product consumption. Endocr Pract. 2008 May-Jun; 14(4): 415-8. DOI: 10. 4158/EP. 14. 4. 415.
34. Chavarro JE, Toth TL, Sadio SM, Hauser R. Soy food and isoflavone intake in relation to semen quality parameters among men from an infertility clinic. Hum Reprod. 2008 Nov; 23(11): 2584-90. DOI: 10. 1093/humrep/den243.
35. Thelen P, Wuttke W, Seidlová-Wuttke D. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer. J Steroid Biochem Mol Biol. 2014 Jan; 139: 290-3. DOI: 10. 1016/j. jsbmb. 2013. 06. 009.
36. Messina M, Messina V. The role of soy in vegetarian diets. Nutrients. 2010 Aug; 2(8): 855-88. DOI: 10. 3390/nu2080855.
37. Jefferson WN, Williams CJ. Circulating levels of genistein in the neonate, apart from dose and route, predict future adverse female reproductive outcomes. Reprod Toxicol. 2011 Apr; 31(3): 272-9. DOI: 10. 1016/j. reprotox. 2010. 10. 001.
38. Whitten PL, Lewis C, Russell E, Naftolin F. Potential adverse effects of phytoestrogens. J Nutr. 1995 Mar; 125(3 Suppl): 771S-776S.
39. Messina M, Melby MK, Kronenberg F, Kurzer MS, Taku K. Letters to the editor. Menopause. 2013 Mar; 20(3): 359-61. DOI: 10. 1097/GME. 0b013e318284e64a.
40. Sirotkin AV, Harrath AH. Phytoestrogens and their effects. Eur J Pharmacol. 2014 Oct 15; 741: 230-6. DOI: 10. 1016/j. ejphar. 2014. 07. 057.
41. Jargin SV. Phytoestrogens and other botanicals: on the problems of evidence-based evaluation. Recent Pat Cardiovasc Drug Discov. 2013 Apr; 8(1): 67-71. DOI: 10. 2174/18722083113079990009.
42. Nikitina NA, Sobenin IA, Myasoedova VA, Korennaya VV, Mel'nichenko AA, Khalilov EM, Orekhov AN. Antiatherogenic effect of grape flavonoids in an ex vivo model. Bull Exp Biol Med. 2006 Jun; 141(6): 712-5. DOI: 10. 1007/s10517-006-0260-7.
43. Orekhov AN, Sobenin IA, Korneev NV, Kirichenko TV, Myasoedova VA, Melnichenko AA, Balcells M, Edelman ER, Bobryshev YV. Antiatherosclerotic therapy based on botanicals. Recent Pat Cardiovasc Drug Discov. 2013 Apr; 8(1): 56-66. DOI: 10. 2174/18722083113079990008.
44. Ryong LH, Tertov VV, Vasil'ev AV, Tutel'yan VA, Orekhov AN. Antiatherogenic and antiatherosclerotic effects of mushroom extracts revealed in human aortic intima cell culture. Drug Dev Res. 1989; 17: 109-17. DOI: 10. 1002/ddr. 430170203.
45. Orekhov AN, Baldenkov GN, Tertov VV, Ryong LH, Kozlov SG, Lyakishev AA, Tkachuk VA, Ruda MYa, Smirnov VN. Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol. 1988; 12 Suppl 6: S66-8.
46. Orekhov AN. Anti-atherosclerotic Drugs from Natural Products. Nat Prod Chem Res. 2013; 1: 121. DOI: 10. 4172/2329-6836. 1000121.
47. Orekhov AN, Pivovarova EM, Sobenin IA, Yakushkin VV, Tertov VV. Use of cell culture for optimisation of direct antiatherogenic therapy with verapamil. Drugs. 1992; 44 Suppl 1: 105-110. DOI: 10. 2165/00003495-199200441-00020.
48. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev. 2004 Feb; 25(1): 49-68.
49. Goldstein JL, Brown MS. Progress in understanding the LDL receptor and HMG-CoA reductase, two membrane proteins that regulate the plasma cholesterol. J Lipid Res. 1984 Dec; 25(13): 1450-61.
50. Jargin SV. Testing of serum atherogenicity in cell cultures: questionable data published. GMS Ger Med Sci. 2012; 10: Doc02. DOI: 10. 3205/000153.
51. Orekhov AN, Melnichenko AA, Sobenin IA. Approach to reduction of blood atherogenicity. Oxid Med Cell Longev. 2014; 2014: 738679. DOI: 10. 1155/2014/738679.
52. Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJ, Rombach I, Brindley D, Savulescu J, Beard DJ, Carr AJ. Use of placebo controls in the evaluation of surgery: systematic review. BMJ. 2014; 348: g3253. DOI: 10. 1136/bmj. g3253.
53. Jargin SV. Invasive procedures with questionable indications. Ann Med Surg. 2014; 3(4): 126-9. DOI: 10. 1016/j. amsu. 2014. 06. 003.
54. Gilliss BM, Looney MR, Gropper MA. Reducing noninfectious risks of blood transfusion. Anesthesiology. 2011 Sep; 115(3): 635-49. DOI: 10. 1097/ALN. 0b013e31822a22d9.
55. Bambauer R, Schiel R, Latza R. Low-density lipoprotein apheresis: an overview. Ther Apher Dial. 2003 Aug; 7(4): 382-90. DOI: 10. 1046/j. 1526-0968. 2003. 00070. x.
56. Parhofer KG. How will new medications affect the lipoprotein apheresis situation in Germany? Atheroscler Suppl. 2013 Jan; 14(1): 71-2. DOI: 10. 1016/j. atherosclerosissup. 2012. 10. 022.
57. Julius U. Updates in apheresis and atherosclerotic research. Ther Apher Dial. 2013 Apr; 17(2): 124. DOI: 10. 1111/1744-9987. 12029.
58. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009 Apr; 29(4): 431-8. DOI: 10. 1161/ATVBAHA. 108. 179564.